Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1122-1130

  Siu, Lillian L ^a   Oza, Amit M ^a   Eisenhauer, Elizabeth A ^a   Firby, Patricia S ^a   Thiessen, Jake J ^a   Michael, Michael ^a   Wainman, Nancy ^a   Manzo, Janet ^a   Feld, Ron ^a   Goldberg, Ronn A ^a   Moore, Malcolm J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DNA TOPOISOMERASE; MANNITOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLLOID; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETHARGY; MALE; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031935226     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1122     Document Type: Article

References (27)

1. Takimoto CH, Arbuck SG: The camptothecins, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 2). Philadelphia, PA, Lippincott-Raven, 1996, pp 463-484
2. Burris HA, Fields SM: Topoisomerase I inhibitors: An overview of the camptothecin analogs. Hematol Oncol Clin North Am 8:333-355, 1994
3. Dancey J, Eisenhauer EA: Current perspectives on camptothecins in cancer treatment. Br J Cancer 74:327-338, 1996
4. Champoux J: Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme. Proc Natl Acad Sci USA73:3488-3491, 1976
5. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
6. Pantazis P, Hinz HR, Mendoza JT, et al: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52:3980-3987, 1992
7. Potmesil M, Giovanella BC, Liu LF, et al: Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10, 11-methylenedioxy-camptothecin, in Potmesil M, Kohn KW (eds): DNA Topoisomerases in Cancer. New York, NY, Oxford University Press, 1991, pp 299-311
8. Potmesil M, Giovanella BC, Wall ME, et al: Preclinical and clinical development of DNA topoisomerase I inhibitors in the United States, in Andoh T (ed): The International Symposium on DNA Topoisomerases in Chemotherapy. New York, NY, CRC, 1993, pp 301-311
9. Chen AY, Yu C, Potmesil M, et al: Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044, 1991
10. Supko JG, Plowman J, Dykes DJ, et al: Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 33: 432, 1992 (abstr 2578)
11. Supko JG, Malspeis L: Pharmacokinetics of the 9-amino and 10, 11-methylenedioxy derivatives of camptothecin in mice. Cancer Res 53:3062-3069, 1993
12. Dahut W, Harold N, Takimoto C, et al: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14:1236-1244, 1996
13. Rubin E, Wood V, Bharti A, et al: A phase I and pharmacokinetic study of a new camptothecin derivative. 9-aminocamptothecin. Clin Cancer Res 1:269-276, 1995
14. Takimoto CH, Dahut W, Marino MT, et al: Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15:1492-1501, 1997
15. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
16. Takimoto CH, Klecker RW, Dahut WL, et al: Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr 655:97-104, 1994
17. D'Argenio DZ, Schumitsky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134, 1979
18. Boxenbaum HG, Riegelman S, Elashoff RM: Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2:123-148, 1974
19. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175, 1978
20. Gibaldi M, Perrier D: Pharmacokinetics. New York, NY, Marcel Dekker, 1982
21. Wagner JG: Pharmacokinetics for the Pharmaceutical Scientist. Lancaster, PA, Technomic, 1993, p 259
22. Jaxel C, Kohn KW, Mansukh C, et al: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465-1469, 1989
23. Sasaki Y, Hakusui H, Mizuno S, et al: A pharmacokinetics and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86:101-110, 1995
24. Canal P, Gay C, Dezeuze A, et al: Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14:2688-2695, 1996
25. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a 90 minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
26. Schiller JH, Kim KM, Hutson P, et al: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial. J Clin Oncol 14:2345-2352, 1996
27. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994